Developing nations demand trillions in climate finance at COP29
HQ team November 14, 2024: The 29th Conference of the Parties (COP29) to the United Nations Framework Convention on Climate Change (UNFCCC), held.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ team November 14, 2024: The 29th Conference of the Parties (COP29) to the United Nations Framework Convention on Climate Change (UNFCCC), held.
The global diabetic population has risen fourfold to 828 million during the last three decades, with more than a quarter living in India,.
HQ Team November 13, 2024: A team of international researchers has developed a non-addictive painkiller that remains inactive until it reaches sites of.
HQ Team November 13, 2024: At COP29 in Baku, Azerbaijan, multilateral development banks (MBDs) announced a commitment to $120 billion in climate financing.
HQ Team November 13, 2024: ALK-Abelló, the Danish pharma company has acquired exclusive rights to Neffy (epinephrine nasal spray) from ARS Pharmaceuticals for.
UN Secretary-General António Guterres outlined a three-point plan to limit global temperature rise to 1.5 degrees Celsius by 2030, including new ways to.
Toxic positivity promotes the belief that individuals should maintain happiness regardless of their circumstances. It discourages negative thoughts, even in situations that naturally.
Novovax Inc., will soon start enrollment for end-stage trials of its Covid-19-Influenza vaccine and stand-alone influenza jab following a nod from the US.
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of.
AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com